LIVE PULSE
4.9 Anthropic CEO Amodei calls for slower AI development and shared safety rules11 src2.6 Agility Robotics unveils Digit 5 humanoid for warehouses and factories2 src2.4 Apple ships rebuilt Siri with Google Gemini, but not in the EU2 src2.2 Siri AI in macOS 27 Golden Gate: FAQ, Germany availability, privacy questions2 src1.7 Sam Altman says OpenAI will not go public in 2026, citing AI safety concerns5 src1.4 OpenAI contractors review real ChatGPT conversations to rate responses, report says2 src1.3 Anthropic data retention policy prompts firms to limit Claude use for sensitive work1 src1.3 CoMem Paper Proposes Shared and Individual Memory Design for LLM Multi-Agent Systems1 src1.3 Paper proposes evolving context parameterization for large language models1 src1.3 Fine-Tuning Vision-Language Models with Listener Gaze for Referring Expressions1 src4.9 Anthropic CEO Amodei calls for slower AI development and shared safety rules11 src2.6 Agility Robotics unveils Digit 5 humanoid for warehouses and factories2 src2.4 Apple ships rebuilt Siri with Google Gemini, but not in the EU2 src2.2 Siri AI in macOS 27 Golden Gate: FAQ, Germany availability, privacy questions2 src1.7 Sam Altman says OpenAI will not go public in 2026, citing AI safety concerns5 src1.4 OpenAI contractors review real ChatGPT conversations to rate responses, report says2 src1.3 Anthropic data retention policy prompts firms to limit Claude use for sensitive work1 src1.3 CoMem Paper Proposes Shared and Individual Memory Design for LLM Multi-Agent Systems1 src1.3 Paper proposes evolving context parameterization for large language models1 src1.3 Fine-Tuning Vision-Language Models with Listener Gaze for Referring Expressions1 src
HEATPULSEAI MAGAZINES
FLIP · FOLLOW · SAVE

ai-in-oncology

topic1 events
papersTODAY 04:00 UTC

arXiv paper reviews barriers to trustworthy AI use in cancer genomics

A revised arXiv paper examines how AI and natural language processing are used to extract and interpret biomedical knowledge in cancer genomics. It argues that clinical adoption has lagged and lays out the barriers, risks and possible pathways needed for trustworthy translation into routine oncology. The work is a review and framing contribution rather than a report of new model results.